Personalis, Inc. (NASDAQ:PSNL) Shares Purchased by Two Sigma Investments LP

Two Sigma Investments LP increased its stake in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 86.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 145,662 shares of the company's stock after acquiring an additional 67,403 shares during the period. Two Sigma Investments LP owned about 0.21% of Personalis worth $842,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Personalis in the fourth quarter valued at approximately $28,000. Stifel Financial Corp grew its holdings in Personalis by 25.0% in the fourth quarter. Stifel Financial Corp now owns 25,000 shares of the company's stock valued at $144,000 after purchasing an additional 5,000 shares during the period. JPMorgan Chase & Co. grew its holdings in Personalis by 2,827.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock valued at $34,000 after purchasing an additional 5,654 shares during the period. Ameriprise Financial Inc. grew its holdings in Personalis by 38.3% in the fourth quarter. Ameriprise Financial Inc. now owns 34,407 shares of the company's stock valued at $199,000 after purchasing an additional 9,535 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in Personalis by 66.6% in the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,168 shares of the company's stock valued at $145,000 after purchasing an additional 10,065 shares during the period. 61.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on PSNL shares. Needham & Company LLC reissued a "buy" rating and issued a $7.00 price objective on shares of Personalis in a report on Thursday, April 10th. Craig Hallum started coverage on Personalis in a report on Monday, March 17th. They issued a "buy" rating and a $8.00 price objective on the stock. HC Wainwright raised their price objective on Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, May 7th. Finally, Guggenheim started coverage on Personalis in a research report on Thursday, May 15th. They issued a "buy" rating and a $6.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Personalis currently has an average rating of "Buy" and a consensus price target of $7.67.

Personalis Price Performance

PSNL opened at $5.21 on Friday. Personalis, Inc. has a 12 month low of $1.14 and a 12 month high of $7.20. The stock has a market capitalization of $460.17 million, a price-to-earnings ratio of -3.10 and a beta of 1.83. The business has a fifty day moving average price of $4.13 and a 200 day moving average price of $4.48.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. The firm had revenue of $20.61 million during the quarter, compared to analysts' expectations of $17.41 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. On average, research analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current year.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.